The age-related eye disease study (AREDS): Design implications AREDS report no. 1

Controlled Clinical Trials

Volumn 20, Issue 6, 1999, Pages 573-600

  Lindblad, A S ^a   Kassoff, A ^a   Kieval, S ^a   Mehu, M ^a   Buehler, J ^a   Eglow, M ^a   Kaufman, F ^a   Margherio, R R ^a   Cox, M S ^a   Garretson, B ^a   Hassan, T ^a   Ruby, A ^a   Trese, M T ^a   Werner, J C ^a   Williams, G A ^a   Regan, V ^a   Manatrey, P ^a   Cumming, K ^a   Zajechowski, M ^a   Falk, R ^a   Streasick, P ^a   Szydlowski, L ^a   Dreyer, R F ^a   Ma, C ^a   Beardsley, C ^a   Crider, H ^a   Capone A , Jr ^a   Aaberg, T M ^a   Martin, D ^a   Saperstein, D ^a   Sternberg P , Jr ^a   Curtis, L ^a   Stribling, B ^a   Gilman, J ^a   Myles, B ^a   Swords, R ^a   Orth, D H ^a   Flood, T P ^a   Civantos, J ^a   DeBustros, S ^a   Packo, K H ^a   MacLeod, C ^a   Morrison, C ^a   Bryant, D A ^a   Doherty, D ^a   Sandoval, S ^a   Seddon, J M ^a   Pinnolis, M K ^a   Jones Devonish, D A ^a   Crouse, V D ^a   Snow, K K ^a   Evans, C ^a   Davis, N ^a   Callahan, C ^a   Walsh, D ^a   Dubois, J ^a   Burton, I ^a   Ferris III, F L ^a   Chew, E Y ^a   Csaky, K ^a   McCarthy, S A ^a   Dabas, K H ^a   Goodman, L ^a   Young Ja Kim, ^a   Lopez, P ^a   Mercer, R ^a   Ayres, L M ^a   LaRean, T ^a   Randall, A ^a   Chicca, M ^a   Ciatto, P F ^a   Kuehl, E ^a   Kivitz, I ^a   Koutsandreas, D ^a   Friberg, T R ^a   Eller, A ^a   Gorin, M B ^a   Alexander, J ^a   Mack, B ^a   Bressler, S B ^a   Bressler, N M ^a   Cassel, G ^a   Goldberg, M ^a   Haller, J A ^a   Ratner, L ^a   Schachat, A P ^a   Sherman, S H ^a   Sunness, J S ^a   Schenning, S ^a   Sackett, C ^a   Cain, D ^a   Emmert, D ^a   George, T ^a   Wheeler, S ^a   Elman, M J ^a   Ballinger, R ^a   Betancourt, A ^a   Glasser, D ^a   Lammlein, J ^a   more..

^a EMMES CORPORATION   (United States)

Author keywords

Age related macular degeneration; Antioxidants; Beta carotene; Cataract; Clinical course; Clinical trial; Vitamin C; Vitamin E; Zinc

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; MINERAL; VITAMIN;

AGE; CATARACT; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; MULTICENTER STUDY; PROGNOSIS; RETINA MACULA DEGENERATION; REVIEW; UNITED STATES;

EID: 0033436360     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(99)00031-8     Document Type: Article

References (54)

1. Sorsby A. Reports on Public Health and Medical Subjects. No 114. London: Her Majesty's Stationary Office, 1966.
2. Kahn H.A., Moorhead H.B. Statistics on Blindness in the Model Reporting Area. 1969-1970. 1973;73-427 USDHEW, PHS Publication No. (NIH), Washington, DC.
3. National Advisory Eye Council. Report of the Retinal and Choroidal Diseases Panel. Vision Research-A National Plan: 1983-1987. Bethesda, MD: U.S. Department of Health and Human Services; 1984.
4. National Advisory Eye Council. Report of the Cataract Panel. Vision Research - A National Plan: 1983-1987. Bethesda, MD: U.S. Department of Health and Human Services; 1984.
5. Thylefors B., Négrel A.D., Pararajasegaram R., Dadzie K.Y. Global data on blindness. Bull WHO. 73(1):1995;115-121.
6. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 109:1991;1109-1114.
7. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 108:1990;816-824.
8. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. updated findings from two clinical trials Arch Ophthalmol. 111:1993;1200-1209.
9. Recurrent choroidal neovascularization after argon laser treatment for neovascular maculopathy. Arch Ophthalmol. 104:1986;503-512.
10. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol. 108:1990;825-831.
11. Hiller R., Sperduto R.D., Ederer F. Epidemiologic associations with nuclear, cortical, and posterior subcapsular cataracts. Am J Epidemiol. 124:1986;926.
12. Leske M.C., Chylack L.T., Wu S.Y.et al. The Lens Opacities Case-Control Study. Arch Ophthalmol. 109:1991;244.
13. Kahn H.A., Leibowitz H.M., Ganley J.P.et al. The Framingham Eye Study, II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol. 106:1977;33-41.
14. Hyman L.G., Lilienfeld A.M., Ferris F.L. III et al. Senile macular degeneration. A case-control study Am J Epidemiol. 118:1983;213-227.
15. Delaney W.V., Oates R.P. Senile macular degeneration. A preliminary study. Ann Ophthalmol. 14:1982;21-24.
16. Maltzman B.A., Mulvihill M.N., Greenbaum A. Senile macular degeneration and risk factors. A case-control study Ann Ophthalmol. 11:1979;1197-1201.
17. Klein R., Davis M.D., Magli Y.L.et al. The Wisconsin age-related maculopathy grading system. Ophthalmol. 98:1991;1128-1134.
18. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 115:1997;741-747.
19. Klein R., Klein B.E.K., Jensen S.C., Meuer S.M. The five-year incidence and progression of age-related maculopathy. The Beaver Dam Study. Ophthalmology. 104:1997;7-21.
20. Fundus photographic risk factors for progression of diabetic retinopathy. Ophthalmol. 98(Suppl):1991;823-833.
21. Klein BEK, Magli YL, Neider MW, et al. Wisconsin system for classification of cataracts from photographs. NTIS Accession No. PB 90-138306.
22. Buring JF, Hennekens CH. In: Prasad K, ed. Nutrients in Cancer Prevention and Treatment. Totowa, NJ: Humana; 1995; pp 223-234.
23. Stampfer M.J., Hennekens C.H., Manson J.E.et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 328:1993;1444-1449.
24. Sperduto R.D., Ferris F.L. 3rd, Kurinij N. Do we have a nutritional treatment for age-related cataract or macular degeneration? Arch Ophthalmol. 108:1990;1403-1405.
25. Newsome D.A., Swartz M., Leone N.C.et al. Oral zinc in macular degeneration. Arch Ophthalmol. 106:1988;192-198.
26. Wu M., Fisher M., DeMets D. Sample sizes for long-term medical trials with time-dependent dropout and event rates. Control Clin Trials. 1:1980;109-121.
27. Ederer F. Shall we count eyes or subjects? Arch Ophthalmol. 89:1973;1-2.
28. Katz J. Two eyes or one? The data analyst's dilemma. Ophthalmic Surg. 19:1988;585-589.
29. Wei L.J., Lachin J.M. Two sample asymptotically distribution-free tests for incomplete multi-variate observations. J Am Stat Assoc. 79:1984;653-661.
30. Kaplan E., Meier P. Nonparametric estimates from incomplete observations. J Am Stat Assoc. 53:1958;457.
31. Turnbull B.W. The empirical distribution function with arbitrarily grouped, censored and truncated data. J Roy Stat Soc Series B. 38:1976;290-295.
32. Finkelstein D.M. A proportional hazards model for interval-censored failure time data. Biometrics. 42:1986;845-854.
33. Lindsey J.C., Ryan L.M. Tutorial in biostatistics. Methods for interval-censored data Stat Med. 17:1998;219-238.
34. Photocoagulation for macular edema. Arch Ophthalmol. 103:1985;1796-1806.
35. Choi S.C., Stablein D.M. Comparing proportions with incomplete data under non-random mechanisms. Stat Med. 7:1988;929-939.
36. Liang K.Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika. 80:1986;55-61.
37. Qaqish B.F., Liang K.-Y. Marginal models for correlated binary responses with multiple classes and multiple levels of nesting. Biometrics. 48:1992;939-950.
38. Wei L.J., Lin D.Y., Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 84:1989;1065-1073.
39. Lee E.W., Wei L.J., Amato D.A. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. Klein J.P., Goel P.K. Survival Analysis. State of the Art:1992;237-247 Kluwer Academic Publishers, Dordrecht.
40. Lan K.K.G., Lachin J.M. Implementation of group sequential logrank tests in a maximum duration trial. Biometrics. 46:1990;759-770.
41. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556.
42. Pocock S.J. Group sequential methods in the design and analysis of clinical trials. Biometrika. 64:1977;191-199.
43. Carson C, PhD, Lee S, Livingston P, et al. Ocular exposure to UV-B in sunlight: The Melbourne visual impairment model. Bull WHO 1996;74(4):353-360.
44. Rosenthal F., West S., Munoz B.et al. Ocular and facial skin exposure to ultraviolet radiation in sunlight. A personal exposure model with application to a worker population Health Physics. 61(1):1991;77-86.
45. The National Eye Institute 25-Item Visual Function Questionaire (VFQ-25). Santa Monica, Calif; RAND, 1996.
46. Ferris F.L. 3rd, Sperduto R.D. Standardized illumination for visual acuity testing in clinical research. Am J Ophthalmol. 94:1982;97-98.
47. Hooper P.L., Visconti L., Garry P.J.et al. Zinc lowers high-density lipoprotein-cholesterol levels. JAMA. 244:1980;1960-1961.
48. Freeland-Graves J.H., Friedman B.J., Han W.H.et al. Effect of zinc supplementation on plasma high-density lipoprotein cholesterol and zinc. Am J Clin Nutr. 35:1982;988-992.
49. Goodwin J.S., Hunt W.C., Hooper P.et al. Relationship between zinc intake, physical activity, and blood levels of high-density lipoprotein cholesterol in a health elderly population. Metabolism. 34:1985;519-523.
50. Black M.R., Medeiros D.M., Brunett E.et al. Zinc supplements and serum lipids in young adult white males. Am J Clin Nutr. 47:1988;970-975.
51. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 330:1994;1029-1035.
52. Hennekens C.H., Buring J.E., Manson J.E.et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 334:1996;1145-1149.
53. Omenn G.S., Goodman G.E., Thornquist M.D.et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 334:1996;1150-1155.
54. Meinert C.L. Clinical Trials and treatment effects monitoring (and comments). Control Clin Trials. 19:1988;515-543.